PhaseBio Pharmaceuticals Long Term Debt

PhaseBio Pharmaceuticals posts a long-term debt of $870K as of June 2022. That compares with $5.4M in the prior-year period — down 83.8% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, PhaseBio Pharmaceuticals's long-term debt was $5.4M. The latest reading is $870K — a 83.8% year-over-year decrease (period ending June 2022). Use the history and growth charts on this page for a longer lookback.

Long-Term Debt is one piece of PhaseBio Pharmaceuticals's financial statement story. At $870K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for PHAS's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; PhaseBio Pharmaceuticals's other metric pages and overview cover the third.

Judging PhaseBio Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in long-term debt easier to interpret. Start with $870K here, then scan peer and history charts to see if the gap is persistent.